Stoke Therapeutics, Inc. will present on its pioneering work to develop the first gene-specific, disease-modifying therapies for genetic epilepsies at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco next week. The technology, Targeted Augmentation of Nuclear Gene Output (TANGO), is designed to restore protein production to normal levels in patients with autosomal dominant disorders in which one copy of a gene is healthy and the other is dysfunctional. Stoke’s lead indication is Dravet Syndrome, a rare and devastating form of genetic epilepsy that affects more than 35,000 patients in the U.S., the European Union and Japan. Dr. Kaye will present data showing that Stoke’s TANGO technology successfully increases production of the key protein missing in Dravet Syndrome, Nav1.1, in a highly precise, durable and controlled manner in mouse models. Stoke’s drug candidate would be the first therapy to address the root cause of Dravet Syndrome and modify the course of the disease.